Pelthos Therapeutics (PTHS) director reports no beneficial ownership on Form 3

Rhea-AI Filing Summary

Pelthos Therapeutics Inc. insider reporting shows that director Andrew J. Einhorn filed an initial ownership statement for the company’s stock. The filing is dated for an event on 12/23/2025 and confirms his status as a director of Pelthos Therapeutics Inc. (ticker PTHS).

In this Form 3, Einhorn reports that he has no securities beneficially owned in Pelthos Therapeutics Inc. as of the event date. The filing is made by a single reporting person and indicates that there are no non-derivative or derivative equity holdings currently attributed to him.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Einhorn Andrew J.

(Last) (First) (Middle)

C/O PELTHOS THERAPEUTICS INC.

4020 STIRRUP CREEK DRIVE, SUITE 110

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/23/2025

3. Issuer Name and Ticker or Trading Symbol
Pelthos Therapeutics Inc. [ PTHS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Andrew J. Einhorn	12/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Pelthos Therapeutics Inc. (PTHS) disclose in this Form 3?

The filing shows that director Andrew J. Einhorn has filed an initial statement of beneficial ownership and reports no securities beneficially owned in Pelthos Therapeutics Inc.

What is the event date for this Pelthos Therapeutics (PTHS) insider ownership filing?

The event requiring the statement occurred on 12/23/2025, as disclosed in the Form 3.

What is Andrew J. Einhorn’s relationship to Pelthos Therapeutics Inc. (PTHS)?

Andrew J. Einhorn is identified as a director of Pelthos Therapeutics Inc. in this ownership report.

How many Pelthos Therapeutics (PTHS) shares does the reporting person own?

The explanation of responses section states that no securities are beneficially owned by the reporting person.

Does this Pelthos Therapeutics (PTHS) Form 3 report any derivative securities?

No. The filing notes that no securities are beneficially owned, which applies to both non-derivative and derivative securities tables.

Is this Pelthos Therapeutics (PTHS) Form 3 filed by more than one reporting person?

No. The report indicates it is a Form filed by One Reporting Person.